ARDX Ardelyx is a biopharmaceutical company that discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the US and internationally.
On 3/2/2022 Jefferies Financial Group Upgraded ARDX from Hold to Buy raising the price target from $1.00 to $5.00
This would be a 581% gain from the current level.
Looking...
Ardelyx , Inc. ARDX had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the company's FDA approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022, that has a potential peak in revenue greater than 500mil per year.
Since ARDX’s Market Cap is only...
Ardelyx shares are trading higher after Ladenburg Thalmann upgraded the stock from Neutral to Buy and announced a $6 price target. Also, Citigroup maintained a Buy rating and raised its price target from $7 to $13.
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and...
Ardelyx, Inc. ARDX yesterday had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the company's FDA approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022, that has a potential peak in revenue greater than 500mil per year.
Since ARDX’s Market Cap is...
Following the negative news that sent this stock into an 82% tailspin there is no viable buy signal aside from a simple long-term play.
Trend is continuing downward slowly. Has yet to find a solid support zone.
By way of Analyst Consensus, upside is above 100% but may take 12-months to materialize.
By way of previous share price average, upside is close to...
The FDA is unlikely to approve Ardelyx`s drug for dialysis patients.
Ardelyx received a letter from the FDA stating that deficiencies in the information provided had been found that would preclude discussion of approvals Ardelyx has sought.
The most likely target is the 1.6usd support line from which it can bounce up.
This is not financial advice. This thesis is exclusively based on technical analysis without catalyst. Bullish trend expected to continue and hit new highs as long as volume is high. Stop loss set at closest support.
Why get subbed to to me on Tradingview?
-TOP author on TradingView
-15+ years experience in markets
-Professional chart break downs
-Supply/Demand Zones
-TD9 counts / combo review
-Key S/R levels
-No junk on my charts
-Frequent updates
-Covering FX/crypto/US stocks
-24/7 uptime so constant updates
ARDX D1::BEST level to BUY 100% gains (SWING)(STOCKS)
IMPORTANT...
This is not financial advise
you do what is make you feeling comfort
ARDX will easy hit
Short Term :
TG1 $7
Long term :
TG2 $7.57
TG3 $8.05
if you like me advise follow me
thanks for your support
This is not financial advise
you do what is make you feeling comfort
ARDX will easy hit
Short Term :
T1 $7
Long term :
T2 $7.57
T3 $8.05
if you like me advise follow me
thanks for your support
This is not financial advise
you do what is make you feeling comfort
ARDX will easy hit
Short Term :
TG1 $7
Long term :
TG2 $7.57
TG3 $8.05
if you like me advise follow me
thanks for your support
Ardelyx, Inc. is a biopharmaceutical company. engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.
NASDAQ
